Condition deep-dive · 9 min read

Osteopenia supplement protocol — how to slow bone loss before it becomes osteoporosis

Updated 2026-05-16 · Reviewed by SupplementScore editors · No sponsorships

Osteopenia is the DEXA-defined window where bone mineral density T-score sits between −1.0 and −2.5 — lower than peak adult bone mass, but not yet in the osteoporotic range. Roughly one in three US women over 50 and one in five men over 50 fall into the osteopenic window. It is not a disease in itself, but it is the leverage point where lifestyle, supplements, and (for a subset) fracture-risk-guided medication can change the trajectory before bones cross into the osteoporotic range where fracture risk rises sharply. The supplement protocol below is for the osteopenic range — the dedicated osteoporosis stack covers the more advanced situation where pharmacological therapy is usually indicated.

Use FRAX, not the T-score alone, to decide whether osteopenia needs medication. The FRAX 10-year fracture risk calculator (or NOGG / NICE thresholds outside the US) is what determines whether someone with osteopenia should be on a bisphosphonate. T-score −1.5 in a 75-year-old with a prior wrist fracture and a parent with hip fracture is a very different risk picture from T-score −1.5 in a 55-year-old with no other risk factors. Supplements do not replace this assessment.

The role of supplements in osteopenia

Three things determine adult bone density: the peak you reached in your twenties, the loss rate after that (steepening around menopause for women and through the seventh decade for men), and your fracture risk (which is bone density combined with falls, frailty, and prior fracture history). Supplements address the second of those — they can modestly slow loss, particularly when calcium, vitamin D, protein, or magnesium intake are inadequate. Resistance training and weight-bearing exercise address bone density and falls simultaneously and have the largest effect size. Pharmacological treatment is reserved for high-fracture-risk individuals, where bisphosphonates, denosumab, and the bone-builders (teriparatide, romosozumab) outperform any supplement combination by a wide margin.

Top supplements with strong evidence

Tier 1 evidence · Foundational, replete to adequacy

Calcium (food-first, with citrate or carbonate as fill-in)

Total intake 1,000–1,200 mg/day from diet + supplement combined; supplement only the gap

The Tang 2007 meta-analysis (29 RCTs, n=63,897) found calcium ± vitamin D reduced fracture risk by 12% and slowed BMD loss in adults ≥50. The clinical move is to estimate dietary calcium intake first (each serving of dairy ≈ 300 mg, sardines ≈ 325 mg per 3 oz, fortified plant milk ≈ 300 mg, leafy greens vary) and supplement only the difference. Calcium carbonate is cheap and well-absorbed with food; calcium citrate is preferred on PPIs or when taken between meals. Avoid single doses >500 mg — absorption falls off and CV-risk concerns from the Bolland 2010 meta-analysis cluster around high-bolus supplemental calcium without dietary balance.

Tier 1 evidence · Replete to functional sufficiency

Vitamin D3

800–2,000 IU/day to reach serum 25(OH)D ≥30 ng/mL; not megadose

Vitamin D is required for calcium absorption and bone mineralisation. The 2005 Bischoff-Ferrari meta-analysis showed 700–800 IU/day reduced hip fracture risk by 26% and non-vertebral fracture by 23%. The VITAL trial of 2,000 IU/day in unselected adults did not reduce fractures overall, suggesting the benefit is concentrated in those replete from deficiency rather than supranormal supplementation. The clinical position: test 25(OH)D, supplement to reach 30–50 ng/mL, then maintain. Avoid the once-weekly mega-bolus 50,000 IU regimens for routine osteopenia care — they don't outperform daily dosing and have signal for paradoxically increased falls in older adults at very high doses.

Tier 1 evidence · MK-7 specifically in postmenopausal women

Vitamin K2 (menaquinone-7, MK-7)

180 µg/day MK-7 form

The Knapen 2013 three-year RCT in 244 postmenopausal women showed MK-7 180 µg/day improved hip and lumbar spine BMD vs placebo. Mechanism: K2 is the cofactor for γ-carboxylation of osteocalcin (which then binds calcium into the bone matrix) and matrix Gla protein (which inhibits vascular calcification). The form matters — MK-7 has a much longer half-life than MK-4 or K1 and so can be dosed once daily at lower microgram amounts. Critical interaction: vitamin K2 directly antagonises warfarin and must be coordinated with the anticoagulation clinic; daily intake should be kept constant if continuing warfarin. DOACs and other anticoagulants are not affected.

Tier 1 evidence · Often-missed cofactor

Magnesium

300–400 mg elemental/day (glycinate, citrate, malate)

Roughly 60% of magnesium in the body is in bone, and magnesium is the cofactor for the enzymes that activate vitamin D. The Orchard 2014 analysis of the Women's Health Initiative (n=73,684 postmenopausal women) found higher magnesium intake was associated with higher hip BMD. Castiglioni 2013 review covers the mechanistic case. Magnesium deficiency is common in older adults (low intake, PPI use, diuretics, malabsorption) and addressing it complements calcium and D rather than competing for absorption. Avoid magnesium oxide (poor bioavailability, laxative effect).

Tier 1 evidence · Underdosed in older adults

Protein — whey or whole-food, 1.0–1.2 g/kg/day

25–30 g protein per meal, 3 meals/day; whey 20–25 g post-resistance training

The PROT-AGE recommendations (Bauer 2013) and ESPEN consensus place older-adult protein intake at 1.0–1.2 g/kg body weight/day — well above the standard RDA of 0.8 g/kg, which was set for nitrogen balance, not for preserving lean mass and bone. Protein is essential for the organic matrix of bone (mostly type I collagen) and supports the muscle mass that pulls on bone to maintain density. The Sahni 2017 cohort showed each 15 g/day increment in protein was associated with 1.8% higher femoral neck BMD. Whey is the cleanest add-on (high leucine, fast absorption) — but legumes, eggs, dairy, and fish all work if the daily total gets there.

Tier 2 evidence · Specific peptides in postmenopausal women

Specific bioactive collagen peptides

5 g/day specific bioactive collagen peptides

The König 2018 randomised trial in 102 postmenopausal women with osteopenia showed 5 g/day of specific bioactive collagen peptides over 12 months improved lumbar spine and femoral neck BMD vs placebo. Mechanism: peptide signalling to osteoblasts plus delivery of glycine, proline, and hydroxyproline as substrate for the bone matrix. Effect size is modest but the safety profile is excellent. Note that not all collagen peptide products are the specific Fortibone-style formulation studied; powder dose was 5 g/day in the trial.

Conditional / situational supplements

Conditional · Creatine + resistance training (older adults)

The Chilibeck 2015 12-month trial of creatine monohydrate 0.1 g/kg/day combined with supervised resistance training in postmenopausal women showed preservation of femoral neck BMD and improvement in lean mass. Creatine alone without resistance training does not move BMD. Useful only as part of an exercise prescription, but in that context — cheap, safe, well-tolerated.

Conditional · Soy isoflavones (perimenopausal/early postmenopausal women)

The Wei 2012 meta-analysis of soy isoflavones in postmenopausal women showed modest improvement in lumbar spine BMD over 6–12 months at doses of 80–120 mg/day isoflavones. Effect is smaller than vitamin K2 or pharmacological therapy. Reasonable add-on for women already using isoflavones for vasomotor symptoms; not a stand-alone treatment for osteopenia.

Conditional · Boron (when dietary intake is low)

Low-quality but consistent signal that boron 3 mg/day modestly reduces urinary calcium and magnesium loss and may modulate oestrogen metabolism. Background dietary intake from fruits, nuts, and vegetables is usually adequate. Reasonable to supplement when diet is consistently poor in plant foods, not as first-line.

What to skip

Medication considerations

The supplements above interact meaningfully with several common medications relevant in the osteopenia population. The medication-interaction layer is one of the most under-recognised parts of bone health.

The lifestyle bedrock

Supplements augment but do not replace the four things that actually drive osteopenic-range outcomes: progressive resistance training (the LIFTMOR trial of high-intensity training in postmenopausal women improved hip BMD significantly), weight-bearing impact activity (walking, jumping, hopping), adequate protein and total energy intake, and fall prevention (vision, footwear, home safety, balance training, medication review). Smoking cessation is high-leverage for bone — smokers lose density faster and heal fractures slower. Alcohol >2 drinks/day accelerates loss. Excess soda intake (especially cola) is associated with lower BMD in observational data, likely via displacement of dairy intake. None of this is replaceable by a supplement protocol; all of it is augmented by one.

Practical layered start. (1) Confirm the DEXA finding and run FRAX with your clinician — supplements are adjunctive, and high FRAX warrants pharmacological evaluation regardless. (2) Lifestyle base: 2× per week progressive resistance training, daily weight-bearing activity, 1.0–1.2 g/kg protein/day. (3) Calculate dietary calcium; supplement only the gap to 1,000–1,200 mg/day total. (4) Test 25(OH)D; supplement 1,000–2,000 IU/day to reach 30–50 ng/mL. (5) Add magnesium 300 mg/day if diet is low. (6) Add vitamin K2 (MK-7) 180 µg/day — verify no warfarin first. (7) For postmenopausal women specifically — consider 5 g/day specific bioactive collagen peptides. (8) Repeat DEXA at 1–2 years; if FRAX or BMD trajectory worsens, escalate to pharmacological therapy.

Sources

Read more: